SV Health Investors
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics
Artios Pharma develops cancer treatments that target DNA damage response pathways, focusing on patient groups with limited existing treatment options.
Alchemab Therapeutics raises £24m Series A extension led by Ono Venture Investment to advance AI-enabled antibody platform
Alchemab identifies naturally occurring protective antibodies using AI and patient data, developing new therapies based on disease resilience rather than traditional target discovery.
NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies
NRG Therapeutics develops oral small-molecule drugs targeting mitochondrial dysfunction, aiming to slow or halt neurodegenerative diseases such as ALS and Parkinson’s through disease-modifying treatments.
TRIMTECH raises £24m seed led by Cambridge Innovation Capital and SV Health Investors to advance neurodegenerative treatments
TRIMTECH Therapeutics develops targeted protein degradation medicines that selectively remove harmful protein aggregates, focusing on neurodegenerative and inflammatory diseases with limited existing treatment options.
More venture news
- 4 Mar 2026
Oxa closes £77m Series D led by National Wealth Fund for autonomous vehicle technology in industrial environments
Series DMobility - 25 Feb 2026
WayveWayve raises a £900m Series D round from leading VCs and automakers to roll out fully driverless tech platform
Series DMobility - 3 Feb 2026
ElevenLabsElevenLabs lands £370m Series D led by Sequoia Capital to double down on human-like AI text to speech model
Series DAI
